A Phase 2 Dose Selection Trial of Candesartan Cilexetil and Amlodipine Besylate to Treat Essential Hypertension
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 384 participants.
Also called NCT02059616
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 384 participants
- Sponsor
- Registry
-
NCT02059616
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Unknown status
Technical summary
Registry record NCT02059616. Randomized; quadruple masking; primary purpose treatment. Start 2014-02 (registry gives no type); primary completion 2015-06 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 2 Dose Selection Trial of Candesartan Cilexetil and Amlodipine Besylate to Treat Essential Hypertension
- Condition
- Essential Hypertension
- Intervention (Drug)
- Amlodipine 5mg
- Intervention (Drug)
- Amlodipine 10mg
- Intervention (Drug)
- Candesartan Cilexetil 8mg
- Intervention (Drug)
- Candesartan cilexetil 16mg
- Lead sponsor
- HK inno.N Corporation
Record details
- Record id
cardio:ct-nct02059616- Content hash
27bfaad723c8a135c75bfa648eda1099e52396f2c90a0adda05e38d13686d7a7